Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in at least one ADH1
BridgeBio's new medicine helped all patients feel better in at least one way. This is much better than the old standard treatment that only helped 46%.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.